 |
This industry report focuses upon the technology and market
trends in the GPCRs target space. Given the central and essential
role GPCRs occupy as a drug target class, it is important for
industry participants to map the landscape in terms of both
biological/technical aspects of the target class as well as the
market/business metrics. |
|
|
|
This report presents the latest industry analysis of the
emerging field of Personalized Medicine. There is increasing
interest in this field driven by the development of a number of
molecular diagnostics-based tests that determine a patient’s genetic
predisposition to a given disease—such as cancer, or to adverse drug
reactions (ADRs). |
|
|
|
This report presents an industry analysis of the High-Content
Analysis Marketplace in both qualitative and quantitative terms.
High-Content Analysis involves the use of instrumentation, reagents,
and informatics to perform multi-parametric analysis of biological
systems ie., lots of different cellular parameters studied in
parallel. High-Content Analysis is crucial in the biological
characterization [fine-structure characterization] of lead compounds
primarily in the drug discovery process. Select Biosciences’
industry tracking of this space involves analyses of the technology
trends as well as market analysis of instrumentation and reagents
that are utilized in High-Content Analysis. Select Biosciences
presents primary market survey data in this report that describe
important qualitative and quantitative metrics in the High-Content
Analysis marketplace—these parameters describe the marketplace in
detail. |
|
|
|
This report presents an industry analysis of the RNAi and
microRNA markets in both qualitative and quantitative terms. Select
Biosciences’ industry tracking of these spaces involves analyses of
the technology trends as well as market analysis. Select Biosciences
presents primary market survey data in this report that describes
the qualitative and quantitative metrics in the RNAi and microRNA
markets. |
|
|
|
In Silico predictive ADME/Tox screening is one of the hottest
areas in drug discovery. It is widely perceived that the early
screening of chemical entities can significantly reduce the
expensive costs associated with late stage failures of drugs due to
poor ADME/Tox properties. This market research report from Select
Biosciences provides an up-to-date overview and analysis of
technology, business, regulatory trends and key product profiles.
|
|
|
|
This is the latest Stem Cells Market Report from Select
Biosciences. This report presents an up-to-date thorough analysis of
the stem cells landscape including quantitative market analysis,
industry metrics, intellectual property landscape as well as all the
major industry events over the past 18 months. The report contains
primary market survey data collected by Select Biosciences from the
stem cell community-provides a complete picture of technology and
market trends. |
|
|
|
Profiles of 119 companies involved in developing RNAi
technologies are presented along with 84 collaborations. They are a
mix of companies that supply reagents and technologies (nearly half
of all) and companies that use the technologies for drug discovery.
Approximately 15 of these are developing RNAi-based therapeutics.
The bibliography contains selected 250 publications that are cited
in the report. |
|
|
|
This report analyzes the technologies and their impact in the
molecular diagnostics marketplace. We present an assessment of all
the technologies of value in this space and which market segments
are impacted and affected by these technologies. |
|
